<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722722</url>
  </required_header>
  <id_info>
    <org_study_id>08-000556</org_study_id>
    <nct_id>NCT00722722</nct_id>
  </id_info>
  <brief_title>The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates</brief_title>
  <official_title>The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients planning to have kidney transplantation who are sensitized to their donors have high
      levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney
      transplant recipients at risk for rejection very early after transplant. This study is trying
      to determine if the drug bortezomib (Velcade ™) can reduce donor specific alloantibodies to a
      level that permits kidney transplantation without a high risk for rejection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to assess the impact of in vivo treatment of bortezomib on anti-human
      leukocyte antigen (HLA) production by normal antibody secreting cells (ASC) in sensitized
      renal allograft candidates. The design involves treatment of subjects with bortezomib using
      one of three dosing regimens (4 doses, 16 doses or 32 doses of bortezomib). Using novel
      assays, anti-HLA production is determined by measuring the bone marrow derived ASC at
      baseline (prior to therapy) and after treatment (at day 14, 3 days after the last bortezomib
      dose). Paired data are used with patients serving as their own controls. Finally, the safety
      of bortezomib is evaluated by monitoring total serum antibody levels and the incidence of
      side effects (primarily neuropathy) at 1 month, the final follow-up point.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Bortezomib Monotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>Response to treatment with Bortezomib (BTZ) alone was defined as a reduction in serum Donor Specific Alloantibody (DSA) levels following treatment. DSA levels were measured prior to treatment and after treatment. A good response occurred if all DSA were reduced. A partial response when a reduction was observed in at least one DSA, but not all DSA. No response occurred when no reduction of any DSA was attained.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>4 dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 doses of bortezomib (1.3mg/m^2 of body surface area)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 doses of bortezomib (1.3mg/m^2 of body surface area)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>32 dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 doses of bortezomib (1.3mg/m^2 of body surface area)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Velcade given in four-dose cycles intravenously (through a vein).</description>
    <arm_group_label>4 dose group</arm_group_label>
    <arm_group_label>16 dose group</arm_group_label>
    <arm_group_label>32 dose group</arm_group_label>
    <other_name>Velcade(TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

               -  Female subject is post-menopausal, surgically sterilized, or she and/or sexual
                  partner are willing to use an acceptable method of birth control (i.e., a
                  hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom
                  with spermicide, or abstinence) for the duration of the study.

               -  Male subject agrees to use an acceptable method for contraception for the
                  duration of the study.

               -  Renal transplant candidates who otherwise meet our acceptance criteria.

               -  Evidence of alloantibody in their serum (panel reactive antibody &gt;20% and
                  specificities determined by single antigen flow bead assay).

               -  Sensitized patients with no living donors or have donor-specific antibody levels
                  too high to undergo successful transplantation using our current protocols (T or
                  B cell crossmatch channel shift &gt;500).

        Exclusion Criteria:

          -  Patient has a platelet count of &lt;30 x 10^9/L within 14 days before enrollment.

               -  Patient has an absolute neutrophil count (ANC) of &lt;1.0 x 10^9/L within 14 days
                  before enrollment.

               -  Patient has &gt;Grade 2 peripheral neuropathy within 14 days before enrollment.

               -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
                  Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
                  uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
                  ischemia or active conduction system abnormalities. Prior to study entry, any
                  electrocardiogram (ECG) abnormality at Screening has to be documented by the
                  investigator as not medically relevant.

               -  Patient has hypersensitivity to bortezomib, boron or mannitol.

               -  Female subject is pregnant or breast-feeding. Confirmation that the subject is
                  not pregnant must be established by a negative serum B-human chorionic
                  gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy
                  testing is not required for post-menopausal or surgically sterilized women.

               -  Patient has received other investigational drugs within14 days before enrollment.

               -  Serious medical or psychiatric illness likely to interfere with participation in
                  this clinical study.

               -  Diagnosed or treated for malignancy within 5 years of enrollment, with the
                  exception of complete resection of basal cell carcinoma or squamous cell
                  carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after
                  curative therapy.

               -  Contraindication to kidney transplantation—active infection, comorbid medical
                  conditions, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Stegall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Diwan TS, Raghavaiah S, Burns JM, Kremers WK, Gloor JM, Stegall MD. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation. 2011 Mar 15;91(5):536-41. doi: 10.1097/TP.0b013e3182081333.</citation>
    <PMID>21283064</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <results_first_submitted>April 21, 2015</results_first_submitted>
  <results_first_submitted_qc>April 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2016</results_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark Stegall</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4 Dose Group</title>
          <description>4 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="P2">
          <title>16 Dose Group</title>
          <description>16 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="P3">
          <title>32 Dose Group</title>
          <description>32 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4 Dose Group</title>
          <description>4 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="B2">
          <title>16 Dose Group</title>
          <description>16 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="B3">
          <title>32 Dose Group</title>
          <description>32 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="3.5"/>
                    <measurement group_id="B2" value="40.4" spread="11.4"/>
                    <measurement group_id="B3" value="39.5" spread="6.6"/>
                    <measurement group_id="B4" value="39.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response to Bortezomib Monotherapy</title>
        <description>Response to treatment with Bortezomib (BTZ) alone was defined as a reduction in serum Donor Specific Alloantibody (DSA) levels following treatment. DSA levels were measured prior to treatment and after treatment. A good response occurred if all DSA were reduced. A partial response when a reduction was observed in at least one DSA, but not all DSA. No response occurred when no reduction of any DSA was attained.</description>
        <time_frame>6 months</time_frame>
        <population>In the 32 dose group, one patient received a kidney transplant with a B-cell flow cytometric crossmatch channel shift of less than 300 after dose 20 and was transplanted with a positive crossmatch donor. This patient was then excluded from further DSA analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>4 Dose Group</title>
            <description>4 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
          </group>
          <group group_id="O2">
            <title>16 Dose Group</title>
            <description>16 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
          </group>
          <group group_id="O3">
            <title>32 Dose Group</title>
            <description>32 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Bortezomib Monotherapy</title>
          <description>Response to treatment with Bortezomib (BTZ) alone was defined as a reduction in serum Donor Specific Alloantibody (DSA) levels following treatment. DSA levels were measured prior to treatment and after treatment. A good response occurred if all DSA were reduced. A partial response when a reduction was observed in at least one DSA, but not all DSA. No response occurred when no reduction of any DSA was attained.</description>
          <population>In the 32 dose group, one patient received a kidney transplant with a B-cell flow cytometric crossmatch channel shift of less than 300 after dose 20 and was transplanted with a positive crossmatch donor. This patient was then excluded from further DSA analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were followed for 6 months. Before each drug dose, subjects were evaluated for possible toxicities that may have occurred after the previous doses(s).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4 Dose Group</title>
          <description>4 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="E2">
          <title>16 Dose Group</title>
          <description>16 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
        <group group_id="E3">
          <title>32 Dose Group</title>
          <description>32 doses of bortezomib (1.3mg/m^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE, v. 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia Grade 1</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anemia Grade 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Grade 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukopenia Grade 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukopenia Grade 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting Grade 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea Grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea Grade 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms Grade 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chills Grade 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue Grade 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue Grade 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgias Grade 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Stegall, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2812</phone>
      <email>Stegall.Mark@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

